Assessments based on changes from baseline at a single time point are bound to obscure the longitudinal aspects of treatment effects and ignore most information regarding the emergence, onset, duration, and variability of symptoms or disease characteristics [ 19].
The assessments focus on changes in three key domains: subjective wrist function (PRWE-G; DASH), objective impairment (Range of motion, grip strength) and quality of life/social engagement (DASH, EuroQol).
Additionally, all outcomes are being measured on baseline and during fumigation period, permitting the assessment of changes on enzymatic activity and neuropsychological effects of pesticides among individuals, populations, and fumigation periods.
Based on these studies, longitudinal assessments of changes in the SIG as a predictor of outcome are underway.
Demonstration of clinical benefit relies on assessment of changes in disease incidence or complications.
Response rates at follow-up (54%) could have biased the assessment of changes on HRQOL, and consequently, the level of agreement.
To best of our knowledge, there are no studies addressing this issue on adolescents, but the results of a study on the assessment of changes in the quality of life using OHIP on adults [ 5] suggest that the differences found between groups may be consistent, regardless of the use of dichotomous or ordinal scoring systems.
In a large series, Brown et al.[ 8] reported that T1W MR response assessment, based on changes in size and number of vertebral metastases, accurately predicts progression of disease in 79% of cases and stable disease in 75% of cases.
In a large series, Brown et al. reported that T1-weighted MR response assessment, based on changes in size and number of vertebral metastases, accurately predicted progression of disease in 79% of cases and stable disease in 75% of cases, but did not predict regression of disease.
The primary end point of the study was the assessment of changes in PSA based on the intention to treat.
